5-HYDROXY OMEPRAZOLE
| Title | Journal |
|---|---|
| Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study. | Biopharmaceutics & drug disposition 20120901 |
| Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. | European journal of clinical pharmacology 20120501 |
| High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120501 |
| Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. | European journal of clinical pharmacology 20120401 |
| [Effect of high altitude hypoxia on the activity and protein expression of CYP2C9 and CYP2C19]. | Yao xue xue bao = Acta pharmaceutica Sinica 20120201 |
| Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. | Drug metabolism and disposition: the biological fate of chemicals 20120101 |
| Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110815 |
| Clinically significant CYP2C inhibition by noscapine but not by glucosamine. | Clinical pharmacology and therapeutics 20100901 |
| CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole. | Journal of clinical pharmacy and therapeutics 20090801 |
| Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. | Journal of clinical pharmacology 20090501 |
| Enantioseparation of omeprazole and its metabolite 5-hydroxyomeprazole using open tubular capillary electrochromatography with immobilized avidin as chiral selector. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081101 |
| Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. | European journal of clinical pharmacology 20071101 |
| Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. | Acta pharmacologica Sinica 20071001 |
| Validation of chromatographic methods: evaluation of detection and quantification limits in the determination of impurities in omeprazole. | Journal of chromatography. A 20070713 |
| Cyp2c19 genotype and omeprazole hydroxylation phenotype in Chinese Li population. | Clinical and experimental pharmacology & physiology 20070101 |
| Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. | BMC clinical pharmacology 20070101 |
| Enantiomeric separation of omeprazole and its metabolite 5-hydroxyomeprazole using non-aqueous capillary electrophoresis. | Journal of chromatography. A 20061006 |
| Determination of omeprazole, hydroxyomeprazole and omeprazole sulfone using automated solid phase extraction and micellar electrokinetic capillary chromatography. | Journal of pharmaceutical and biomedical analysis 20060911 |
| Analysis of omeprazole and 5-OH omeprazole in human plasma using hydrophilic interaction chromatography with tandem mass spectrometry (HILIC-MS/MS)--eliminating evaporation and reconstitution steps in 96-well liquid/liquid extraction. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060102 |
| Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. | Clinical pharmacology and therapeutics 20051201 |
| Analysis of omeprazole, midazolam and hydroxy-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050925 |
| The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. | Clinical pharmacokinetics 20050101 |
| Metabolism of omeprazole after two oral doses in children 1 to 9 months old. | Proceedings of the Western Pharmacology Society 20050101 |
| Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. | British journal of clinical pharmacology 20040901 |
| Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. | Basic & clinical pharmacology & toxicology 20040901 |
| Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. | Journal of clinical pharmacology 20040601 |